LungLife AI (LLAI) Competitors GBX 9.35 -0.15 (-1.58%) (As of 12/20/2024 05:12 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitors LLAI vs. PRM, GENI, VRCI, IDHC, DMTR, LLA, DXRX, AGL, YGEN, and ABDXShould you be buying LungLife AI stock or one of its competitors? The main competitors of LungLife AI include Proteome Sciences (PRM), GENinCode (GENI), Verici Dx (VRCI), Integrated Diagnostics (IDHC), Deepmatter Group (DMTR), LLA.L,0P0001T9GN,0 (LLA), Diaceutics (DXRX), ANGLE (AGL), Yourgene Health (YGEN), and Abingdon Health (ABDX). These companies are all part of the "diagnostics & research" industry. LungLife AI vs. Proteome Sciences GENinCode Verici Dx Integrated Diagnostics Deepmatter Group LLA.L,0P0001T9GN,0 Diaceutics ANGLE Yourgene Health Abingdon Health Proteome Sciences (LON:PRM) and LungLife AI (LON:LLAI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, community ranking, institutional ownership and risk. Which has more volatility and risk, PRM or LLAI? Proteome Sciences has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. Comparatively, LungLife AI has a beta of -0.3, indicating that its stock price is 130% less volatile than the S&P 500. Which has stronger earnings and valuation, PRM or LLAI? Proteome Sciences has higher revenue and earnings than LungLife AI. Proteome Sciences is trading at a lower price-to-earnings ratio than LungLife AI, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProteome Sciences£4.04M2.24-£4.08M-£0.01-307.20LungLife AI£98.57K29.08-£4.47M-£0.13-71.92 Is PRM or LLAI more profitable? LungLife AI has a net margin of 0.00% compared to Proteome Sciences' net margin of -101.07%. Proteome Sciences' return on equity of 0.00% beat LungLife AI's return on equity.Company Net Margins Return on Equity Return on Assets Proteome Sciences-101.07% N/A -19.25% LungLife AI N/A -48.59%-27.28% Does the MarketBeat Community believe in PRM or LLAI? Proteome Sciences received 162 more outperform votes than LungLife AI when rated by MarketBeat users. CompanyUnderperformOutperformProteome SciencesOutperform Votes16257.04% Underperform Votes12242.96% LungLife AIN/AN/A Do institutionals and insiders believe in PRM or LLAI? 23.0% of Proteome Sciences shares are owned by institutional investors. Comparatively, 42.5% of LungLife AI shares are owned by institutional investors. 19.5% of Proteome Sciences shares are owned by insiders. Comparatively, 48.4% of LungLife AI shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media refer more to PRM or LLAI? In the previous week, Proteome Sciences' average media sentiment score of 0.00 equaled LungLife AI'saverage media sentiment score. Company Overall Sentiment Proteome Sciences Neutral LungLife AI Neutral SummaryProteome Sciences beats LungLife AI on 7 of the 12 factors compared between the two stocks. Ad Weiss RatingsNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. Get LungLife AI News Delivered to You Automatically Sign up to receive the latest news and ratings for LLAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart LLAI vs. The Competition Export to ExcelMetricLungLife AIDiagnostics & Research IndustryMedical SectorLON ExchangeMarket Cap£2.87M£27.75M£5.14B£1.88BDividend YieldN/A5.44%5.09%5.54%P/E Ratio-71.922.0090.051,810.29Price / Sales29.082,398.621,117.14382,807.21Price / Cash2.2811.4243.0428.42Price / Book0.333.044.782.91Net Income-£4.47M£53.40M£120.31M£156.83M7 Day Performance-1.58%-3.11%-1.92%-1.92%1 Month Performance6.86%-0.11%11.51%17.93%1 Year Performance-81.07%-14.32%30.61%29.50% LungLife AI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LLAILungLife AIN/AGBX 9.35-1.6%N/A-81.1%£2.87M£98,566.00-71.9215PRMProteome SciencesN/AGBX 2.68+1.1%N/A-38.3%£7.91M£4.04M-291.00240Gap UpGENIGENinCodeN/AGBX 3.80-3.2%N/A-30.2%£6.72M£2.60M-78.522,300Gap UpVRCIVerici DxN/AGBX 2.63+1.9%N/A-73.5%£6.37M£4.33M-131.2519Gap DownIDHCIntegrated DiagnosticsN/AGBX 0.44-2.6%N/A+23.3%£2.58M£4.75B14.756,692Gap DownDMTRDeepmatter GroupN/AGBX 0.03+22.2%N/AN/A£1.33M£1.04M-0.11N/AGap DownLLALLA.L,0P0001T9GN,0N/AGBX 15flatN/AN/A£0.00N/A-125.0015High Trading VolumeDXRXDiaceutics2.4147 of 5 starsGBX 125.40+4.9%GBX 160+27.6%+39.8%£105.93M£26.09M-3,983.33151Analyst ForecastNews CoverageAGLANGLE1.0959 of 5 starsGBX 10.70-0.5%GBX 70+554.2%-17.0%£34.51M£2.02M-153.57650YGENYourgene HealthN/AGBX 0.52flatN/A+0.0%£16.43M£29.67M-51.50253ABDXAbingdon HealthN/AGBX 7.95+9.7%N/A-10.6%£15.07M£6.13M-899.0084High Trading Volume Related Companies and Tools Related Companies Proteome Sciences Competitors GENinCode Competitors Verici Dx Competitors Integrated Diagnostics Competitors Deepmatter Group Competitors LLA.L,0P0001T9GN,0 Competitors Diaceutics Competitors ANGLE Competitors Yourgene Health Competitors Abingdon Health Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:LLAI) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LungLife AI, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LungLife AI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
